The important takeaway is that these gene therapies can be cost-effective and don’t break the bank. Too often the discussion of a therapeutic’s price is fixated on eye-popping numbers and not value. It’s laudable that ICER has redirected us to the discussion of value.
ICER’s Positive Cost-Effectiveness Assessment Lends Support For New Sickle Cell Disease Gene Therapies
